Enhanced Allergic Inflammation of Der p 2 Affected by Polymorphisms of MD-2 Promoter

En Chih Liao1, Chia Wei Hsieh2, Ching Yun Chang2

  • 1Center for Translational Medicine, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of BioIndustry Technology, Da Yeh University, Changhua, Taiwan.; Department of Medical Technology, Jen Ten College of Medicine, Nursing and Management, Miaoli, Taiwan.

Abstract

Insights

Single nucleotide polymorphisms in the Myeloid differentiation-2 (MD-2) promoter influence allergic inflammation. These MD-2 promoter SNPs may indicate a predisposition to Der p 2-induced allergic responses.

Area of Science:

  • Immunology
  • Genetics

Background:

  • Myeloid differentiation-2 (MD-2) is recognized for its role in lipopolysaccharide (LPS) recognition and Toll-like receptor 4 (TLR4)-mediated signaling in inflammatory disorders.
  • The specific involvement of MD-2 in allergic inflammation remains largely uncharacterized.
  • Investigating genetic variations in the MD-2 promoter is crucial for understanding its contribution to allergic conditions.

Purpose of the Study:

  • To determine if single nucleotide polymorphisms (SNPs) in the MD-2 promoter affect MD-2 expression.
  • To elucidate the relationship between allergic responses to Dermatophagoides pteronyssinus group 2 allergen (Der p 2) and MD-2 promoter SNPs.

Main Methods:

  • Analysis of MD-2 promoter function, cytokine secretion, and mRNA expression in 73 allergic individuals with varying MD-2 gene promoter variants.
  • Culture of peripheral blood mononuclear cells with LPS and Der p 2, followed by mRNA extraction and cytokine analysis.
  • Measurement of cytokines in culture supernatants.

Main Results:

  • Patients with MD-2 promoter SNPs (rs1809441/rs1809442) exhibited increased mRNA expression of MD-2, IgE heavy chain (Cε), and IL-8.
  • Der p 2 stimulation further upregulated MD-2 and IL-8 expression.
  • SNPs were associated with elevated levels of IL-1β, IL-6, IL-8, IL-10, and TNF-α following Der p 2 and LPS stimulation.

Conclusions:

  • High levels of pro-inflammatory cytokines induced by Der p 2 are predetermined by specific MD-2 promoter SNPs (rs1809441/rs1809442).
  • These SNPs can serve as biomarkers for the pathological phenotype of Der p 2-induced allergic inflammation by influencing cytokine secretion.
  • Understanding the genetic basis of MD-2 function offers insights into allergic disease mechanisms.

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Allergic Reactions02:06

Allergic Reactions

Overview
33.9K
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
152
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
217
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
8.4K